Identification
- Generic Name
- Fenbufen
- DrugBank Accession Number
- DB08981
- Background
Fenbufen is a non-steroidal anti-inflammatory drug used primarily to treat inflammation in osteoarthritis, ankylosing spondylitis, and tendinitis. It can also be used to relieve backaches, sprains, and fractures. Fenbufen is available as a capsule or tablet sold with the brand names Cepal, Cinopal, Cybufen, Lederfen, and Reugast. Fenbufen acts by preventing cyclooxygenase from producing prostaglandins which can cause inflammation.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Fenbufen (DB08981)
- Weight
- Average: 254.2806
Monoisotopic: 254.094294314 - Chemical Formula
- C16H14O3
- Synonyms
- 3-(4-Biphenylylcarbonyl)propionic acid
- 3-(4-Phenylbenzoyl)propionic acid
- 4-(4-Biphenylyl)-4-oxobutyric acid
- Fenbufen
- Fenbufén
- Fenbufène
- Fenbufenum
- gamma-oxo(1,1'-biphenyl)-4-butanoic acid
- External IDs
- CL 82,204
- CL-82204
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Acute gouty arthritis •••••••••••• ••••••• Treatment of Osteoarthritis (oa) •••••••••••• ••••••• Treatment of Post operative pain •••••••••••• ••••••• Treatment of Postoperative dental pain •••••••••••• ••••••• Treatment of Rheumatoid arthritis •••••••••••• ••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Fenbufen may decrease the excretion rate of Abacavir which could result in a higher serum level. Abciximab The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Abciximab. Acebutolol Fenbufen may decrease the antihypertensive activities of Acebutolol. Aceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with Fenbufen. Acemetacin The risk or severity of adverse effects can be increased when Fenbufen is combined with Acemetacin. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- ATC Codes
- M01AE05 — Fenbufen
- Drug Categories
- Acids, Carbocyclic
- Agents causing hyperkalemia
- Agents that produce hypertension
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Antiinflammatory and Antirheumatic Products
- Antiinflammatory and Antirheumatic Products, Non-Steroids
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Enzyme Inhibitors
- Musculo-Skeletal System
- Nephrotoxic agents
- Non COX-2 selective NSAIDS
- Peripheral Nervous System Agents
- Propionates
- Sensory System Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbonyl compounds
- Direct Parent
- Alkyl-phenylketones
- Alternative Parents
- Biphenyls and derivatives / Butyrophenones / Gamma-keto acids and derivatives / Benzoyl derivatives / Aryl alkyl ketones / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives
- Substituents
- Alkyl-phenylketone / Aromatic homomonocyclic compound / Aryl alkyl ketone / Benzenoid / Benzoyl / Biphenyl / Butyrophenone / Carboxylic acid / Carboxylic acid derivative / Gamma-keto acid
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- biphenyls, 4-oxo monocarboxylic acid (CHEBI:31599)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 9815R1WR9B
- CAS number
- 36330-85-5
- InChI Key
- ZPAKPRAICRBAOD-UHFFFAOYSA-N
- InChI
- InChI=1S/C16H14O3/c17-15(10-11-16(18)19)14-8-6-13(7-9-14)12-4-2-1-3-5-12/h1-9H,10-11H2,(H,18,19)
- IUPAC Name
- 4-{[1,1'-biphenyl]-4-yl}-4-oxobutanoic acid
- SMILES
- OC(=O)CCC(=O)C1=CC=C(C=C1)C1=CC=CC=C1
References
- Synthesis Reference
U.S. Patent 3,784,701.
- General References
- Not Available
- External Links
- KEGG Drug
- D01344
- PubChem Compound
- 3335
- PubChem Substance
- 310264942
- ChemSpider
- 3218
- BindingDB
- 50240374
- 24830
- ChEBI
- 31599
- ChEMBL
- CHEMBL277522
- ZINC
- ZINC000000001427
- PharmGKB
- PA166049176
- Wikipedia
- Fenbufen
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule Capsule 300 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 185-187 U.S. Patent 3,784,701. - Predicted Properties
Property Value Source Water Solubility 0.0121 mg/mL ALOGPS logP 3.07 ALOGPS logP 3 Chemaxon logS -4.3 ALOGPS pKa (Strongest Acidic) 4.22 Chemaxon pKa (Strongest Basic) -7.5 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 54.37 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 72.49 m3·mol-1 Chemaxon Polarizability 27.47 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 176.5976043 predictedDarkChem Lite v0.1.0 [M-H]- 159.4243 predictedDeepCCS 1.0 (2019) [M+H]+ 176.4729043 predictedDarkChem Lite v0.1.0 [M+H]+ 161.78232 predictedDeepCCS 1.0 (2019) [M+Na]+ 167.87546 predictedDeepCCS 1.0 (2019)
Drug created at June 10, 2014 15:46 / Updated at June 12, 2020 16:52